ATR and adenocarcinoma: Compared to EGFR-mutant adenocarcinoma, EGFR-mutant SCC exhibited a higher mutation ATR frequency [odds ratio (OR): 8.44, 95% CI: 0.87–420.30, P=0.037], BRCA1 (OR: 8.44, 95% CI: 0.87–420.30, P=0.037), and NF1 (OR: 8.44, 95% CI: 0.87–420.30, P=0.037), and more CNVs of EGFR (OR: 4.28, 95% CI: 1.03–21.60, P=0.028) (Table S3).